(Alliance News) - GlaxoSmithKline PLC on Wednesday said its ViiV Healthcare subsidiary secured European marketing consent for the Tivicay medication to treat children with HIV.
ViiV Healthcare is majority owned by GSK, with Pfizer Inc and Shionogi Ltd as shareholders.
The European Commission granted marketing authorisation for a five milligramme dispersible tablet of Tivicay to treat HIV-1 in sufferers aged at least four weeks old.
"Today's authorisation is a really important milestone towards enabling children to have access to age-appropriate formulations of HIV medicine. Globally there are approximately 1.7 million children living with HIV and around 100,000 children dying each year from AIDS which is why we won't stop doing all that we can to ensure that no child living with HIV is left behind," ViiV Chief Executive Officer Deborah Waterhouse said.
GSK shares were 0.5% higher at 1,373.80 pence each in London on Wednesday morning. Pfizer shares were down 0.2% in pre-market trade in New York, after closing down 1.6% at USD37.18 each on Tuesday.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)